Revolutionizing Cancer Care: All4Cure and OnCare Launch Value-Based Clinical Pathway for Newly Diagnosed Multiple Myeloma Patients

All4Cure and OnCare, a network of community oncology practices dedicated to advancing patient-centric care, have joined forces to build and release the Value-Based Clinical Pathway for Multiple Myeloma. This pathway is a resource to empower both clinicians and patients to make informed decisions about Myeloma care. It is based on the following principles:

1. Treats patients with Newly Diagnosed Multiple Myeloma (NDMM) in a manner that aims to achieve and maintain measurable residual disease (MRD) negativity.1-8

2. Prioritizes enrollment into clinical trials.

3. Encourages the enrollment of patients and their oncologists into All4Cure.

4. For patients with relapsed refractory multiple myeloma (RRMM), review treatments and outcomes of similar patients using MyelomaMap reports generated from All4Cure’s real world database.

5. Incorporates measures to prevent or mitigate toxicities and infections.  

6. Sequences treatments to minimize short term and long term toxicities.

7. Simplifies the frequency of oral drug regimens to once daily when feasible to increase adherence.

Please download the entire clinical pathway here.